Skip To Main Content
Boscolo Bielo L on Muck Rack

Boscolo Bielo L

As seen in: Oxford University Press (OUP)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Boscolo Bielo

Contact Boscolo Bielo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

|
By Luca Boscolo Bielo, Boscolo Bielo L, Boscolo Bielo, Elena Guerini
| Oxford University Press (OUP)
Cancer of unknown primary origin (CUP), encompassing cancers of unidentified primary origin, represents 2% of all malignant solid tumor diagnosis1 and establish an unmet clinical need due to poor long term clinical outcomes.2 Approximately half of CUP present as adenocarcinomas of unknown primary site (ACUPs), characterized by mucin production, tubule formation, and immunohistochemistry (IHC) findings that define the histologic subtype without pinpointing the exact origin.2 The remaining...
Open in Who Shared Issue with article?

A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data

|
By Boscolo Bielo L, Meric-Bernstam F
| ncbi.nlm.nih.gov
doi: 10.1016/j.ejca.2023.112958. Online ahead of print. Affiliations Affiliations 1 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA.
Open in Who Shared Issue with article?

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments - PubMed

|
By Del Mastro L, Boscolo Bielo L
| ncbi.nlm.nih.gov
doi: 10.1016/j.ejca.2023.112944. Online ahead of print. Affiliations Affiliations 1 Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan 20141, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. 2 Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Open in Who Shared Issue with article?
See all 3 articles